Alex Gerber, DO
Ophthalmology · Middletown, RINPI 1114156841
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.6%), consulting fees and gifts — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Glaukos Corporation at 56.0% of the total. 2025 is the largest year on record at $7,828, more than ten times the $463 reported in 2019. Among ophthalmology clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 222 payments — averaging $65.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$8K
- Sun Pharmaceutical Industries Inc.$1K
- AbbVie$1K
- Alcon$896
- Biotissue Holdings Inc.$556
- Sight Sciences, Inc.$555
- plus $2K from 15 others
What the payments were for
- Consulting fees$7,17549%
- Food & beverage$7,40351%
- Gifts$450%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 14 | $8,194 |
| Sun Pharmaceutical Industries Inc. | 37 | $1,284 |
| AbbVie(2 entities) | 64 | $1,259 |
| Alcon | 17 | $896 |
| Biotissue Holdings Inc. | 13 | $556 |
| Sight Sciences, Inc. | 14 | $555 |
| Lensar, Inc. | 2 | $293 |
| Bausch & Lomb Americas Inc. | 10 | $247 |
| Kala Pharmaceuticals, Inc. | 12 | $195 |
| Ocular Therapeutix, Inc. | 5 | $192 |
| Oyster Point Pharma, Inc. | 5 | $175 |
| NEW World Medical,inc. | 4 | $170 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $114 |
| Novartis | 5 | $108 |
| Rayner Intraocular Lenses Limited | 6 | $107 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $103 |
| Shire North American Group Inc | 4 | $65 |
| Coopervision Inc. | 2 | $49 |
| Zogenix Inc. | 1 | $22 |
| Tarsus Pharmaceuticals, Inc. | 1 | $20 |
| Harrow Eye, LLC | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iDose$1,000
- CEQUA$486
- Prokera$372
- OMNI(R) SURGICAL SYSTEM (US)$371
- LENSAR LASER SYSTEM$293
- AmnioGraft$247
- DURYSTA$230
- iDoseTR$200
- iStent Trabecular Micro-Bypass System Model iS3$159
- EYSUVIS$148
- TRYPTYR$129
- Rhopressa$128
- Rocklatan$128
- Kahook Dual Blade$127
- Clearpath$127
- Ahmed Glaucoma Valve$127
- Streamline$127
- Via360$127
- DEXTENZA$118
How this compares
$14,623 in reported general payments places this provider in the 90th percentile of 69 ophthalmology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 97 | $42,527 |
| RestasisCyclosporine | 21 | $13,781 |
| Prednisolone Acetate | 402 | $13,107 |
| CequaCyclosporine | 16 | $12,261 |
| RocklatanNetarsudil Mesylat/Latanoprost | 17 | $10,695 |
| CombiganBrimonidine Tartrate/Timolol | 42 | $9,109 |
| Ketorolac Tromethamine | 374 | $6,385 |
| Ofloxacin | 424 | $4,645 |
| Lotemax SmLoteprednol Etabonate | 17 | $4,360 |
| Latanoprost | 234 | $3,426 |
| Alphagan PBrimonidine Tartrate | 12 | $2,832 |
| Timolol Maleate | 53 | $2,047 |
| Brimonidine Tartrate | 22 | $1,517 |
| Dorzolamide Hcl | 28 | $394 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 20 | $338 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,259 | $68,250172 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,284 | $12,26116 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $103 | $4,36017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 69 ophthalmology providers in Rhode Island.
Other ophthalmology in Middletown
- Charles CollinsMiddletown$2K
- Sarah AnisProvidence$163K
- Sarah LevyWakefield$148K
- Nermin GraiseWarwick$60K
- Jesse RichmanProvidence$30K
- Yoash EnzerProvidence$11K
- Giulio DiamanteJohnston$6K
- David TienProvidence$6K
- Leah KammerdienerWarwick$6K
- Nikolas RaufiJohnston$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.